Exelixis
EXEL
#1826
Rank
A$16.50 B
Marketcap
A$61.57
Share price
-1.20%
Change (1 day)
12.37%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): A$3.63

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$3.36. In 2023 the company made an earnings per share (EPS) of A$0.92 an increase over its 2022 EPS that were of A$0.80.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$3.63
2023A$0.9214.61%
2022A$0.80-22.97%
2021A$1.04100%
2020A$0.52-65.09%
2019A$1.50-53.91%
2018A$3.25333.96%
2017A$0.75-260.61%
2016A-$0.47-58.75%
2015A-$1.13-42.45%
2014A-$1.965.3%
2013A-$1.86

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
A$15.72 367.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$1.92-42.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$20.22 502.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$2.91-13.23%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$10.31 207.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$4.19 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$5.32 58.32%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
A-$5.18-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.19-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA